Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 22

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 22
---
 gross proceeds of $11,702,826, and after deducting
the sales commissions and estimated
expenses payable by us, our as adjusted net tangible
book value as of December 1, 2025 would have been
approximately ($7.49) million, or ($0.23) per share. This represents an immediate
increasein net tangible book value of $0.59 per
share to existing stockholders and an immediate
decrease in net tangible book value of $1.54 per share to new investors
in this offering.

The following table
illustrates this calculation
on a per share basis. The as adjusted information is illustrative only and will
change based on the actual
price to the public, the actual number
of shares sold and other terms of the offering
determined at the time shares of our Common
Stock are sold pursuant to this prospectus supplement.
The as adjusted information assumes that all of our Common Stock in the aggregate
amount of $11,702,826 is sold at the assumed offering
price of $1.31 per share, the last reported sale
price of our Common Stock on Nasdaq on December 1, 2025.
The shares sold in this offering, if any, will
be sold from time to time at various prices.

| Offering price per share                                                           
 Net tangible book value per share as of September 30, 2025                         |     |   |  1.31 
 (0.83 | ) |
|:-----------------------------------------------------------------------------------|:----|:--|------:|:--|
| Increase in net tangible book value per share attributable to this offering        |     | $ |  0.59 |   |
| As adjusted net tangible book value per share after giving effect to this offering |     | $ | (0.23 | ) |
| Decrease in net tangible book value per share to new investors in this offering    |     | $ | (1.54 | ) |

The above table is
based on 23,178,116 shares of Common Stock outstanding as of September 30, 2025, and excludes
the following:

| ● | 267,695 shares of Common Stock issuable in connection with the acquisition of Renovaro Cube 
 as contingent consideration;                                                                |
| ● | 626,983 shares of Common Stock issuable upon the exercise of warrants at a weighted average 
 exercise prices of $9.09 per share;                                                         |
| ● | 350